SCHEMBL4592845

SCHEMBL4592845

NC(=O)C(c1ccccc1)n1cnnn1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
NOTUM Q6P988 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.40
RAB9A P51151 1/20 0.38
CYP19A1 P11511 1/20 0.38
PKM P14618 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
EPHX1 P07099 1/20 0.37
HMOX1 P09601 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17825837 0.79 CYP19A1 (0.59) CYP19A1
SCHEMBL27494651 0.74 CYP19A1 (0.57) KMT2AMEN1CYP19A1CYP1A2CYP2D6
SCHEMBL4581851 0.74 NOTUM (0.42) SMN1; SMN2KMT2AKDM4EMEN1NOTUM
SCHEMBL4312003 0.73 SMN1; SMN2 (0.38) SMN1; SMN2KMT2AKDM4EMEN1NOTUM
SCHEMBL11499232 0.72 TSHR (0.41) CYP19A1CYP2D6EPHX1LMNA
SCHEMBL29788839 0.70 CYP2D6 (0.44) KMT2AKDM4EMEN1NOTUMNPSR1
SCHEMBL29788853 0.70 CYP2D6 (0.44) KMT2AKDM4EMEN1NOTUMNPSR1
SCHEMBL29788864 0.70 CYP2D6 (0.44) KMT2AKDM4EMEN1NOTUMNPSR1
SCHEMBL4371708 0.69 TBXAS1 (0.43) SMN1; SMN2KMT2AKDM4EMEN1NPSR1
SCHEMBL29185684 0.69 ELANE (0.38) SMN1; SMN2KMT2AKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9430113-B2 Electrically-conductive article with improved bus region EASTMAN KODAK COMPANY (US) 2016-08-30 US disclosed
US-9405423-B2 Article with electrically-conductive silver connector wire pattern EASTMAN KODAK COMPANY (US) 2016-08-02 US disclosed
US-9405196-B2 Method for preparing electrically-conductive silver images EASTMAN KODAK COMPANY (US) 2016-08-02 US disclosed
US-9304395-B2 Conductive element precursor and conductive pattern formation EASTMAN KODAK COMPANY (US) 2016-04-05 US disclosed
US-20160062238-A1 CONDUCTIVE ELEMENT PRECURSOR AND CONDUCTIVE PATTERN FORMATION BANK OF AMERICA, N.A. 2016-03-03 US disclosed
US-9261787-B1 Conductive element precursor and conductive pattern formation EASTMAN KODAK COMPANY (US) 2016-02-16 US disclosed
US-9247640-B2 Silver halide conductive element precursor and devices EASTMAN KODAK COMPANY (US) 2016-01-26 US disclosed
US-9235130-B2 Method for preparing transparent conductive silver patterns EASTMAN KODAK COMPANY (US) 2016-01-12 US disclosed
US-20150338739-A1 METHOD FOR PREPARING TRANSPARENT CONDUCTIVE SILVER PATTERNS BANK OF AMERICA, N.A., AS AGENT 2015-11-26 US disclosed
US-20150338738-A1 METHOD FOR PREPARING ELECTRICALLY-CONDUCTIVE SILVER IMAGES KODAK REALTY INC. 2015-11-26 US disclosed
US-20150338969-A1 ARTICLE WITH ELECTRICALLY-CONDUCTIVE SILVER CONNECTOR WIRE PATTERN BANK OF AMERICA, N.A., AS AGENT 2015-11-26 US disclosed
US-20150338970-A1 ELECTRICALLY-CONDUCTIVE ARTICLE WITH IMPROVED BUS REGION BANK OF AMERICA, N.A., AS AGENT 2015-11-26 US disclosed
US-20150316848-A1 CONDUCTIVE ELEMENT PRECURSOR AND CONDUCTIVE PATTERN FORMATION BANK OF AMERICA, N.A. 2015-11-05 US disclosed
US-20150216043-A1 SILVER HALIDE CONDUCTIVE ELEMENT PRECURSOR AND DEVICES BANK OF AMERICA, N.A., AS AGENT 2015-07-30 US disclosed
US-8362017-B2 N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening EXELIXIS, INC. (US) 2013-01-29 US disclosed
US-20080096892-A1 C-Kit Modulators And Methods Of Use EXELIXIS, INC. (US) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096892-A1 C-Kit Modulators And Methods Of Use KIT, PRKCH, PRKCB SMN1; SMN2 3206/4885KMT2A 1897/4885KDM4E 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.